Memory impairment in the D2. mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688
Experimental Physiology · 2023-09 · 108 (9) · 1108-1117
DOI: 10.1113/ep091274 ↗At a glance
Journal article in Experimental Physiology, published online on 2023-07-06. Written by Catherine A Bellissimo and 8 co-authors. Institution: School of Kinesiology & Health Science, York University, Toronto, ON, Canada. Major MEDLINE topics: Muscular Dystrophy, Duchenne. Cited 15 times so far (Crossref); 59 references. The full text is freely available (open access, CC BY 4.0). Funded by: Natural Sciences and Engineering Research Council of Canada, Canada Foundation for Innovation.
Abstract (original language)
Memory impairments have been well documented in people with Duchenne muscular dystrophy (DMD). However, the underlying mechanisms are poorly understood, and there is an unmet need to develop new therapies to treat this condition. Using a novel object recognition test, we show that recognition memory impairments in D2. mdx mice are completely prevented by daily treatment with the new adiponectin receptor agonist ALY688 from day 7 to 28 of age. In comparison to age‐matched wild‐type mice, untreated D2. mdx mice demonstrated lower hippocampal mitochondrial respiration (carbohydrate substrate), greater serum interleukin‐6 cytokine content and greater hippocampal total tau and Raptor protein contents. Each of these measures was partly or fully preserved after treatment with ALY688. Collectively, these results indicate that adiponectin receptor agonism improves recognition memory in young D2. mdx mice.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Kinesiology & Health Science, York University, Toronto, ON, Canada.
- Muscle Health Research Centre, York University, Toronto, Canada.
- Department of Health Sciences, Brock University, St Catharines, ON, Canada.
- Department of Biology, York University, Toronto, Ontario, Canada.
ORCID profiles: Catherine A Bellissimo, Christopher G R Perry
Funding
- Natural Sciences and Engineering Research Council of Canada
- Canada Foundation for Innovation
Cite
APA
Bellissimo, C. A., Castellani, L. N., Finch, M. S., Murugathasan, M., Gandhi, S., Sweeney, G., Abdul-Sater, A. A., MacPherson, R. E. K., & Perry, C. G. R. (2023). Memory impairment in the D2. mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688. Experimental Physiology, 108(9), 1108-1117. https://doi.org/10.1113/ep091274
Vancouver
Bellissimo CA, Castellani LN, Finch MS, Murugathasan M, Gandhi S, Sweeney G, et al. Memory impairment in the D2. mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688. Experimental Physiology. 2023;108(9):1108-1117. doi:10.1113/ep091274
BibTeX
@article{Bellissimo2023,
author = {Bellissimo, Catherine A and Castellani, Laura N and Finch, Michael S and Murugathasan, Mayoorey and Gandhi, Shivam and Sweeney, Gary and Abdul-Sater, Ali A and MacPherson, Rebecca E K and Perry, Christopher G R},
title = {Memory impairment in the D2. mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688},
journal = {Experimental Physiology},
year = {2023},
volume = {108},
number = {9},
pages = {1108--1117},
doi = {10.1113/ep091274}
}
EUVIMED